New Icon pact expands biomarker offerings

Icon has gained several new technologies from Proteome Sciences to help it bolster the biomarker work it does for drug developers. "This complements Icon's extensive portfolio of biomarker development and analysis services to help sponsors identify, implement, and interpret the right biomarkers to inform their preclinical and clinical drug development," comments John Allinson, VP biomarker lab services, ICON development solutions. Story

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.